- Home
- PHAR vs FMNB Comparison
PHAR vs FMNB Comparison
Compare PHAR & FMNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- FMNB
- Stock Information
- Founded
- PHAR 1988
- FMNB 1887
- Country
- PHAR Netherlands
- FMNB United States
- Employees
- PHAR N/A
- FMNB N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- FMNB Major Banks
- Sector
- PHAR Health Care
- FMNB Finance
- Exchange
- PHAR Nasdaq
- FMNB Nasdaq
- Market Cap
- PHAR 1.0B
- FMNB 555.3M
- IPO Year
- PHAR N/A
- FMNB N/A
- Fundamental
- Price
- PHAR $14.27
- FMNB $14.52
- Analyst Decision
- PHAR Strong Buy
- FMNB Buy
- Analyst Count
- PHAR 3
- FMNB 2
- Target Price
- PHAR $30.00
- FMNB $15.50
- AVG Volume (30 Days)
- PHAR 12.8K
- FMNB 84.4K
- Earning Date
- PHAR 10-23-2025
- FMNB 10-22-2025
- Dividend Yield
- PHAR N/A
- FMNB 4.61%
- EPS Growth
- PHAR N/A
- FMNB N/A
- EPS
- PHAR N/A
- FMNB 1.34
- Revenue
- PHAR $339,836,000.00
- FMNB $169,441,000.00
- Revenue This Year
- PHAR $16.63
- FMNB $20.80
- Revenue Next Year
- PHAR $6.77
- FMNB $8.33
- P/E Ratio
- PHAR N/A
- FMNB $11.01
- Revenue Growth
- PHAR 22.44
- FMNB 0.20
- 52 Week Low
- PHAR $7.31
- FMNB $11.58
- 52 Week High
- PHAR $17.08
- FMNB $16.29
- Technical
- Relative Strength Index (RSI)
- PHAR 54.65
- FMNB 47.53
- Support Level
- PHAR $13.63
- FMNB $14.83
- Resistance Level
- PHAR $15.61
- FMNB $15.15
- Average True Range (ATR)
- PHAR 0.93
- FMNB 0.24
- MACD
- PHAR -0.13
- FMNB -0.08
- Stochastic Oscillator
- PHAR 35.98
- FMNB 7.55
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About FMNB Farmers National Banc Corp.
Farmers National Banc Corp is a one-bank holding company engaged in financial activities, including securities underwriting and dealing, insurance agency and underwriting activities, and merchant banking activities. It operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The company has two operating segments of business; the Bank segment, and the Trust segment, out of which the majority of the company's revenue is derived from the bank segment.